Three-component tear substitute as preoperative support in glaucoma surgery

Close metadata

PURPOSE

This study investigates the effect of preoperative preparation with the three-component tear substitute Stillavit on the outcomes of glaucoma surgery in patients on long-term topical glaucoma therapy.

MATERIAL AND METHODS

The study included 63 patients (63 eyes) with glaucoma, among them 30 (30 eyes) were women and 33 (33 eyes) were men. Group 1 consisted of 33 patients (33 eyes) receiving long-term topical antihypertensive therapy with preservatives and tear substitute Stillavit 3 times a day for 1 month as preoperative preparation. Group 2 included 30 patients (30 eyes) receiving similar antihypertensive therapy who were not prescribed preoperative medications. All patients underwent a comprehensive ophthalmological examination and computer tomography of the filtering blebs (FB) on Visante system (Carl Zeiss Meditec, Germany) before surgery, as well as 1 week, 1, 3, and 6 months after surgery.

RESULTS

Mean intraocular pressure (IOP) elevation at 6 months postoperatively was significantly higher in the group that did not undergo preoperative preparation with a tear substitute, compared to the group of patients who received the tear substitute Stillavit preoperatively. According to anterior segment optical coherence tomography, a greater number of favorable diffuse FB were noted in the group that received the tear substitute Stillavit in preparation for surgery — 87.9%, while in group 2 (without preparation) — 66.7%. Odds ratio calculation between the two groups revealed that preoperative preparation with the tear substitute Stillavit reduced the odds of IOP elevation to 20 mm Hg or higher at 3 months postoperatively by more than 10 times.

CONCLUSION

The use of tear substitute Stillavit in preparation for anti-glaucoma surgery reduces the chances of IOP elevation in the early postoperative period by more than 10 times, which may indicate a reduction in the rate of FB scarring due to the beneficial effect of the drug’s components on the precorneal tear film.

Keywords:

glaucoma surgery

glaucoma

bleb

optical tomography

artificial tear solution

Authors:

Makashova N.V.

Krasnov Research Institute of Eye Diseases

ORCID: 0000-0003-1989-6612

Vasillyeva A.E.

Medical Center “Stolitsa”

ORCID: 0000-0001-5981-2423

Kolosova O.Yu.

Medical Center “Stolitsa”

ORCID: 0000-0001-6342-4888

Received:

06.04.2024

Accepted:

29.04.2024

List of references:

Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
Glatz M, Riedl R, Glatz W, et al. Blindness and visual impairment in Central Europe. PLoS One. 2022. https://doi.org/10.1371/journal.pone.0261897
Erichev VP. Refractory glaucoma: treatment features. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2000;116(5):8-10. (In Russ.).
Lapochkin VI, Svirin AV, Korchuganova EA. A new operation in the treatment of refractory glaucoma — limbosclerectomy with valvular drainage of the supraciliary space. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2001;117(1):9-11. (In Russ.).
Baranov IYa, Bortsov VN, Konstantinova LM. On a method of increasing the effectiveness of antiglaucomatous operations. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 1991;(3):9-13. (In Russ.).
Alekseev IB, Moshetova LK, Zubkova AA. New non-penetraring operation — anexternalization of a scleral sinus with uveoskleral auto-drainage in the treatment of patients with primary open angle glaucoma. Glaucoma. 2012;(2):44-49. (In Russ.).
Takhchidi HP, Ivanov DI, Bardasov DB. Remote results of a microinvasive nonpenetrating deep sclerectomy. Ophthalmosurgery = Oftal’mokhirurgiya. 2003;(3):14-17. (In Russ.).
Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Canaloplasty for primary open-angle glaucoma: long-term outcome. Br J Ophthalmol. 2010;94(11): 1478-1482. https://doi.org/10.1136/bjo.2009.163170
Nikolashin SI, Machekhin VA. Non-penetrating deep scleroticectomy with a drainage of a Shlemm’s channel in treatment of a primary open angle glaucoma. Ophthalmosurgery = Oftal’mokhirurgiya. 2002;(1):17-20. (In Russ.).
Astakhov SYu, Astakhov YuS, Zumbulidze NG. Current trends of development of non-penetraring surgery of glaucoma. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2004;(3):4-7. (In Russ.).
Körber N. Kanaloplastik ab interno — eine minimalinvasive Alternative [Canaloplasty ab interno — a Minimally Invasive Alternative]. Klin Monbl Augenheilkd. 2017;234(8):991-995. (In Germ.). https://doi.org/10.1055/s-0042-123829
Markelova EV, Ovchinnikova OV, Khokhlova AS, Dogadova LP, Kostiushko AV, Pnyukhtina MS. The role of matrix metalloproteinase 9 and its inhibitors in scarring processes following surgery for primary open-angle glaucoma. Patologicheskaya fiziologiya i eksperimental`naya terapiya. 2019; 63(4):72-80. (In Russ.). https://doi.org/10.25557/0031-2991.2019.04.72-80
Erichev VP, Ambartsumyan KG. The preservatives and secondary dry eye syndrome in long-term topical open-angle glaucoma therapy. Nacional’nyj zhurnal Glaukoma. 2011;(2):59-66. (In Russ.).
Volkova NV, Shchuko AG, Yuryeva TN, Malyshev VV. Risk factors for inadequate formation of outflow tracts after non-penetrating deep sclerectomy. Baykal’skiy meditsinskiy zhurnal. 2006;(7). Accessed Feb 25, 2024. (In Russ.). https://cyberleninka.ru/article/n/faktory-riska-neadekvatnogo-formirovaniya-putey-ottoka-posle-nepronikayuschey-glubokoy-sklerektomii
Bessmertny AM. Risk factors of excessive scarring in patients with primary open-angle glaucoma. Glaucoma. 2005;(3):34-36. (In Russ.).
Lebedev OI, Kalizhnikova EA, Kovalevsky VV, Yavorsky AE. Factors of effectiveness of modified non-penetrating deep sclerectomy. Oftal’mologicheskiye vedomosti. 2011;(4). Accessed Febr 28, 2024. (In Russ.). https://cyberleninka.ru/article/n/faktory-effektivnosti-modifitsirovannoy-nepronikayuschey-glubokoy-sklerektomii
Keidel LF, Schworm B, Langer J, Luft N, Herold T, Hagenau F, Klaas JE, Priglinger SG, Siedlecki J. Scleral Thickness as a Risk Factor for Central Serous Chorioretinopathy and Pachychoroid Neovasculopathy. J Clin Med. 2023;12(9):3102. https://doi.org/10.3390/jcm12093102
Alekseev IB, Soshina MM, Belskaya KI, et al. Evaluation of the hypotensive efficacy of antiglaucoma surgery: a retrospective analysis. RMJ. Clinical Ophthalmology = RMZh. Klinicheskaya oftal’mologiya. 2020;20(1):8-14. (In Russ.).
Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin Ophthalmol. 2011;5: 623-631. https://doi.org/10.2147/OPTH.S17876
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-355. https://doi.org/10.1097/IJG.0b013e31815c5f4f
Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011;95(6):869-875. https://doi.org/10.1136/bjo.2010.189449
Breusegem C, Spielberg L, Van Ginderdeuren R, Vandewalle E, Renier C, Van de Veire S, Fieuws S, Zeyen T, Stalmans I. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010;117(7):1324-1330. https://doi.org/10.1016/j.ophtha.2009.11.038
Egorova GB, Averich VV. Reducing cytotoxic action of the preservative employed in ophthalmic hypotensive medications with tear replacement therapy. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(3): 48-56. (In Russ.). https://doi.org/10.17116/oftalma2018134348
Vagge A, Bonino M, Rolando M, Macrì A, Traverso CE, Iester M. The utility of an artificial substitute to improve corneal sensitivity in glaucomatous patients on chronic therapy with prostaglandin analogs. J Ocul Pharmacol Ther. 2015;31(5):286-290. https://doi.org/10.1089/jop.2014.0131
Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111(12):2186-92. https://doi.org/10.1016/j.ophtha.2004.06.023.PMID:15582072.
Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye Contact Lens. 2019;45(1): 11-18. PMID: 30199425; PMCID: PMC6298827. https://doi.org/10.1097/ICL.0000000000000544
Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study. J Ocul Pharmacol Ther. 2015;31(6):323-329. https://doi.org/10.1089/jop.2014.0115
Trzeciecka A, Paterno JJ, Toropainen E, Koskela A, Podracka L, Korhonen E, Kauppinen A, Kaarniranta K, Smedowski A. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016;788:12-20. https://doi.org/10.1016/j.ejphar.2016.06.014
Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction. J Glaucoma. 2016;25(9):770-774. https://doi.org/10.1097/IJG.0000000000000495
Lee TH, Sung MS, Heo H, Park SW. Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One. 2018;13(1):e0191398. https://doi.org/10.1371/journal.pone.0191398
Brzheskiy VV, Kalinina IV, Popov VYu. New possibilities of drug-based therapy in patients with corneoconjunctival xerosis. RMJ. Clinical Ophthalmology = RMZh. Klinicheskaya oftal’mologiya. 2016;16(1):39-46. (In Russ.).

Close metadata